Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifyi...
Alzinova AB is a biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease. The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics. Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.

List your booth number for exhibitions, ask us